Abstract:Neovascular diseases, such as many cancers and ocular disorders, are life threatening and devastating. Although anti-vascular endothelial growth factor A (VEGF-A) therapy is available, many patients are not responsive and drug resistance can develop. To try to overcome these problems, combination therapy targeting VEGF-A and platelet-derived growth factor B (PDGF-B) was tested. However, one obvious drawback was that the other VEGF and PDGF family members were not inhibited and therefore could compensate. Indeed, this was, at least to some extent, demonstrated by the disappointing outcomes. To this end, we designed novel multi-targeted inhibitors that can block most of the VEGF and PDGF family members simultaneously by making a fusion protein containing the ligand-binding domains of vascular endothelial growth factor receptor 1 (VEGFR1), vascular endothelial growth factor receptor 2 (VEGFR2) and platelet-derived growth factor receptor beta (PDGFRβ), which can therefore act as a decoy blocker for most of the VEGF and PDGF family members. Indeed, in cultured cells, the novel inhibitors suppressed the migration and proliferation of both vascular endothelial cells and smooth muscle cells, and abolished VEGFR2 and PDGFRβ activation. Importantly, in a choroidal neovascularization model in vivo, the novel inhibitor inhibited ocular neovascularization more efficiently than the mono-inhibitors against VEGFR or PDGFR alone respectively. Mechanistically, a genome-wide microarray analysis unveiled that the novel inhibitor regulated unique sets of genes that were not regulated by the mono-inhibitors, further demonstrating the functional uniqueness and superiority of the novel inhibitor. Together, we show that the multi-targeted inhibitors that can block VEGFR1, VEGFR2 and PDGFRβ simultaneously suppress pathological angiogenesis more efficiently than monotherapy, and may therefore have promising therapeutic value for the treatment of neovascular diseases.

Therapeutic Paradigm Of Dual Targeting Vegf And Pdgf For Effectively Treating Fgf-2 Off-Target Tumors

Clinical development of dual tyrosine kinase inhibitors targeting vascular endothelial growth factor receptor and platelet- derived growth factor receptor

Dual Blockade of Vascular Endothelial Growth Factor (VEGF) and Basic Fibroblast Growth Factor (FGF-2) Exhibits Potent Anti-Angiogenic Effects.

PDGF-CC Underlies Resistance to VEGF-A Inhibition and Combinatorial Targeting of Both Suppresses Pathological Angiogenesis More Efficiently

Dual Roles of Endothelial FGF-2–FGFR1–PDGF-BB and Perivascular FGF-2–FGFR2–PDGFRβ Signaling Pathways in Tumor Vascular Remodeling

Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy

HER2-targeted Tumor immunotherapy

Antiangiogenic therapy: how far is it to upgrade?

Recent advances of dual FGFR inhibitors as a novel therapy for cancer

Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy

Advances In Combination Of Antiangiogenic Agents Targeting Vegf-Binding And Conventional Chemotherapy And Radiation For Cancer Treatment

Tumour PDGF-BB Expression Levels Determine Dual Effects of Anti-Pdgf Drugs on Vascular Remodelling and Metastasis

Targeting Pericytes with a PDGF-B Aptamer in Human Ovarian Carcinoma Models

Combined Tumor- and Neovascular-"Dual Targeting" Gene/Chemo-Therapy Suppresses Tumor Growth and Angiogenesis.

Novel multi-targeted inhibitors suppress ocular neovascularization by regulating unique gene sets

Anti-Angiogenic Therapy: Strategies to Develop Potent VEGFR-2 Tyrosine Kinase Inhibitors and Future Prospect

A Novel Antitumor Strategy: Simultaneously Inhibiting Angiogenesis and Complement by Targeting VEGFA/PIGF and C3b/C4b.

Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment

The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis

Tumor Cell-Derived Placental Growth Factor Sensitizes Antiangiogenic and Antitumor Effects of Anti-Vegf Drugs

Role Of Pericytes In Resistance To Antiangiogenic Therapy